Krystal Biotech Inc (KRYS)
170.85
-5.54
(-3.14%)
USD |
NASDAQ |
Nov 04, 16:00
171.06
+0.21
(+0.12%)
After-Hours: 20:00
Krystal Biotech Revenue (Quarterly): 70.28M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 70.28M |
March 31, 2024 | 45.25M |
Date | Value |
---|---|
December 31, 2023 | 42.14M |
September 30, 2023 | 8.556M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
8.556M
Minimum
Sep 2023
70.28M
Maximum
Jun 2024
41.56M
Average
43.70M
Median
Revenue (Quarterly) Benchmarks
Bioventus Inc | 151.22M |
ADMA Biologics Inc | 107.19M |
Axsome Therapeutics Inc | 87.17M |
Amicus Therapeutics Inc | 126.67M |
Sarepta Therapeutics Inc | 362.93M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 15.57M |
Total Expenses (Quarterly) | 49.22M |
EPS Diluted (Quarterly) | 0.53 |
Enterprise Value | 4.508B |
Gross Profit Margin (Quarterly) | 91.45% |
Profit Margin (Quarterly) | 22.15% |
Earnings Yield | 2.14% |
Operating Earnings Yield | 0.08% |
Normalized Earnings Yield | 0.9774 |